Marketer of Revlimid® (lenalidomide), Celgene, has signed a definitive agreement to acquire Juno Therapeutics in a deal worth up to US$9 B less than three weeks after it acquired Impact Biomedicines for an upfront payment of US$1.1 B. While the acquisition bolsters Celgene’s pipeline with Juno’s chimeric antigen receptor T cell (CAR-T) therapy, JCAR017, which is in clinical development to target multiple indications in oncology, it leaves an uncertain future for Celgene’s other CAR-T partner, bluebird bio with which it is developing bb21217, an anti-B-cell maturation antigen (anti-BCMA) for relapsed/refractory multiple myeloma.